Gwen A. Fyfe
Directeur/Membre du Conseil chez Molecular Partners, Inc.
Profil
Gwen A.
Fyfe is currently a Director at Molecular Partners, Inc. She previously served as a Director at Pharmacyclics LLC in 2010-2011, an Independent Director at Array BioPharma, Inc. in 2012-2019, a Director at Cascadian Therapeutics LLC in 2016-2018, an Independent Director at Infinity Pharmaceuticals, Inc. in 2012-2016, and a Vice President-BioOncology at Genentech, Inc. in 1997-2009.
She also served as an Independent Director at Igenica Biotherapeutics, Inc. and as a Director at Molecular Partners AG in 2017-2021.
Dr. Fyfe holds a doctorate degree from Washington University School of Medicine.
Postes actifs de Gwen A. Fyfe
| Sociétés | Poste | Début |
|---|---|---|
Molecular Partners, Inc.
 Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Directeur/Membre du Conseil | - |
Anciens postes connus de Gwen A. Fyfe
| Sociétés | Poste | Fin |
|---|---|---|
| MOLECULAR PARTNERS AG | Directeur/Membre du Conseil | 21/04/2021 |
| ARRAY TECHNOLOGIES, INC. | Directeur/Membre du Conseil | 30/07/2019 |
| CASCADIAN THERAPEUTICS INC (USA) | Directeur/Membre du Conseil | 09/03/2018 |
| INFINITY PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 17/06/2016 |
| PHARMACYCLICS, INC. | Directeur/Membre du Conseil | 30/06/2011 |
Formation de Gwen A. Fyfe
| Washington University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| MOLECULAR PARTNERS AG | Health Technology |
| Entreprise privées | 6 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC was a clinical-stage biopharmaceutical company, which focused on the development of therapeutic products for the treatment of cancer. Its product ONT-380, was an orally active and selective small-molecule HER2 inhibitor. The firm also developed preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on August 23, 1985 and was headquartered in Bothell, WA. | Health Technology |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Health Technology |
